{"id":155973,"date":"2026-11-05T09:29:16","date_gmt":"2026-11-05T09:29:16","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/155973\/"},"modified":"2026-11-05T09:29:16","modified_gmt":"2026-11-05T09:29:16","slug":"liver-cancer-diagnostics-market-outlook-reveals-emerging","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/155973\/","title":{"rendered":"Liver Cancer Diagnostics Market Outlook Reveals Emerging"},"content":{"rendered":"

\"Liver<\/a><\/p>\n

Liver Cancer Diagnostics Market<\/p>\n

The liver cancer diagnostics market is undergoing significant expansion, driven by advancements in medical technology and growing awareness about early detection. This sector is poised to see considerable growth in the coming years due to improvements in diagnostic methods and increasing investments in oncology research.<\/p>\n

Current and Projected Market Size of the Liver Cancer Diagnostics Market

\nThe liver cancer diagnostics market has demonstrated robust growth in recent times. It is expected to rise from $10.32 billion in 2025 to $11.07 billion in 2026, marking a compound annual growth rate (CAGR) of 7.3%. The historical growth is largely due to the rising prevalence of chronic liver diseases, increasing cases of hepatocellular carcinoma, expansion of hospital diagnostic facilities, heightened awareness about early cancer screening, and improvements in imaging and pathology techniques.<\/p>\n

Download a free sample of the liver cancer diagnostics market report:

\nhttps:\/\/thebusinessresearchcompany.com\/sample_request?id=61882845&type=smp&name=Liver%20Cancer%20Diagnostics%20Market%20Report%202026&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Nov_PR<\/p>\n

Looking ahead, the market is forecasted to expand further, reaching $14.75 billion by 2030, with an anticipated CAGR of 7.4%. This future growth will be fueled by the wider adoption of precision oncology diagnostics, increasing preference for non-invasive testing methods, expansion of molecular testing technologies, growing investments in cancer research, and the enhanced use of AI-assisted diagnostic platforms. Key trends shaping the market include the broader use of advanced molecular diagnostics, growing reliance on imaging-based early detection tools, integration of biomarker-driven screening techniques, expansion of personalized oncology diagnostics, and a heightened focus on catching cancer at early stages.<\/p>\n

Major Players Leading the Liver Cancer Diagnostics Industry

\nA number of prominent companies are active in the liver cancer diagnostics landscape, including Abbott Laboratories, F Hoffmann La Roche Ltd, Qiagen NV, Thermo Fisher Scientific Inc, Siemens Healthineers, Illumina Inc, Koninklijke Philips NV, Epigenomics AG, Digna Biotech SL, Biocept Inc, Danaher Corporation, Foundation Medicine Inc, Agilent Technologies Inc, Genemed Biotechnologies Inc, Merck KGaA, Fujifilm Medical Systems USA Inc, GE Healthcare, Advanced Cell Diagnostics Inc, Oxford Gene Technology, Leica Biosystems Nussloch GmbH, Exiqon AS, BioGenex Laboratories Inc, OncoCyte Corporation, Guardant Health Inc, Exact Sciences Corporation, Grail Inc, Freenome Holdings Inc, Natera Inc, Personal Genome Diagnostics Inc, and Thrive Earlier Detection Corp.<\/p>\n

View the full liver cancer diagnostics market report:

\nhttps:\/\/thebusinessresearchcompany.com\/report\/liver-cancer-diagnostics-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Nov_PR<\/p>\n

Notably, in December 2024, Metropolis Healthcare Ltd., an Indian diagnostics firm, acquired Core Diagnostics for $0.0278 billion. This acquisition is designed to boost Metropolis’ advanced cancer-testing capabilities and strengthen its presence across northern and eastern India, reinforcing its leadership within specialized diagnostics. Core Diagnostics specializes in liver cancer testing, offering targeted diagnostic services in the region.<\/p>\n

Innovative Trends Accelerating Growth in Liver Cancer Diagnostics

\nLeading companies in this market are focusing on developing sophisticated biomarker-based assays and diagnostic algorithms to increase accuracy and support earlier detection of liver cancer. Biomarker-based assays use specific biological indicators to detect disease, resulting in faster and more precise diagnoses. For example, in November 2023, Roche Diagnostics introduced the Elecsys PIVKA-II assay and Elecsys GAAD algorithm. The PIVKA-II assay identifies elevated levels of the PIVKA-II biomarker linked with hepatocellular carcinoma, improving early cancer detection in high-risk patients. Meanwhile, the GAAD algorithm combines multiple markers, like PIVKA-II and AFP, to enhance diagnostic accuracy and facilitate better clinical decision-making.<\/p>\n

Breakdown of Segments Covered in the Liver Cancer Diagnostics Market

\nThe liver cancer diagnostics market is categorized into several key segments:

\n1) By Type: Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatoblastoma

\n2) By Screening Method: Laboratory Testing, Imaging, Biopsy, Other Screenings

\n3) By Technology: Fluorescent In Situ Hybridization (FISH), Immunohistochemical (IHC), Other Technologies

\n4) By End Use: Hospitals and Diagnostic Laboratories, Academic and Research Institutes.<\/p>\n

Further sub-segmentation includes:

\n– For Hepatocellular Carcinoma: Early-Stage and Advanced-Stage

\n– For Cholangiocarcinoma: Intrahepatic and Extrahepatic

\n– For Hepatoblastoma: Pure and Mixed Types.<\/p>\n

This comprehensive segmentation allows for targeted analysis of market dynamics across different diagnostic approaches and types of liver cancer.<\/p>\n

New strategic additions in our 2026 market reports include market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, along with updated graphics and tables.<\/p>\n

Reach out to us:

\nThe Business Research Company: https:\/\/www.thebusinessresearchcompany.com\/,

\nAmericas +1 310-496-7795,

\nEurope +44 7882 955267,

\nAsia & Others +44 7882 955267 & +91 8897263534,

\nEmail us at info@tbrc.info.<\/p>\n

Follow Us On:

\nLinkedIn: https:\/\/in.linkedin.com\/company\/the-business-research-company,

\nTwitter: https:\/\/twitter.com\/tbrc_info,

\nYouTube: https:\/\/www.youtube.com\/channel\/UC24_fI0rV8cR5DxlCpgmyFQ<\/p>\n

Learn More About The Business Research Company

\nWith over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.<\/p>\n

This release was published on openPR.
\n <\/p>\n